BHV-7000 for Bipolar Disorder
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called BHV-7000 for individuals with bipolar I disorder. The goal is to determine if the treatment is safe and tolerable over an extended period. Those who completed an earlier related study and are not pregnant or breastfeeding might be suitable candidates for this trial. The researchers aim to ensure the treatment's safety and effectiveness for everyday use in managing bipolar I disorder. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant advancements in bipolar I disorder treatment.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
Is there any evidence suggesting that BHV-7000 is likely to be safe for humans?
Research has shown that BHV-7000 is generally safe for people. In previous studies, participants tolerated doses up to 120 mg daily for 15 days well, which exceeds the doses tested in some current studies. Importantly, no serious adverse reactions were reported. Additionally, BHV-7000 did not cause the common side effects associated with similar medications. This makes it a promising option for those considering participation in a clinical trial for bipolar disorder.12345
Why do researchers think this study treatment might be promising?
BHV-7000 is unique because it targets bipolar disorder in a novel way. While most treatments for bipolar disorder, like mood stabilizers and antipsychotics, often focus on balancing neurotransmitters like serotonin and dopamine, BHV-7000 works differently. It targets a specific ion channel in the brain, which could lead to more precise regulation of brain activity. Researchers are excited about this approach because it has the potential to reduce side effects and improve effectiveness compared to current treatments. This could be a game-changer for individuals who haven't found relief with existing options.
What evidence suggests that BHV-7000 might be an effective treatment for bipolar disorder?
Research has shown that BHV-7000 has been safe and effective in some early studies, particularly for seizure-related conditions. However, a recent study on bipolar disorder did not demonstrate a clear benefit in reducing symptoms compared to a placebo. Despite this, the medication was safe and well-tolerated, with no serious side effects. This suggests that while BHV-7000 might not yet be proven effective for bipolar disorder, it remains safe for further research.12367
Are You a Good Fit for This Trial?
This trial is for individuals who have bipolar I disorder and have completed the parent study BHV7000-204. Women of childbearing potential (WOCBP) must not be pregnant, breastfeeding, or lactating to participate.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BHV-7000 to assess long-term safety and tolerability
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BHV-7000
Trial Overview
The focus of this study is on assessing the long-term safety and tolerability of a medication called BHV-7000 in people with bipolar I disorder.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Biohaven Therapeutics Ltd.
Lead Sponsor
Citations
1.
ir.biohaven.com
ir.biohaven.com/news-releases/news-release-details/biohaven-presents-new-data-bhv-7000-once-daily-extended-releaseBiohaven Presents New Data with BHV-7000 Once-Daily ...
Reported expanded safety results from BHV-7000 Phase 1 multiple ascending dose studies, including the once-daily extended-release formulation being evaluated ...
2.
psychiatrictimes.com
psychiatrictimes.com/view/bhv-7000-for-bipolar-disorder-fails-in-phase-2-3-trialBHV-7000 for Bipolar Disorder Fails in Phase 2/3 Trial
BHV-7000 failed to achieve statistical significance in a bipolar trial but was safe and well-tolerated, with no serious adverse events.
3.
neurologylive.com
neurologylive.com/view/antiseizure-agent-bhv-7000-demonstrates-positive-safety-efficacy-results-phase-1-studyAntiseizure Agent BHV-7000 Demonstrates Positive Safety, ...
Antiseizure Agent BHV-7000 Demonstrates Positive Safety, Efficacy Results in Phase 1 Study. Findings from the study further confirmed target ...
NCT06419582 | BHV-7000 Acute Treatment of Bipolar Mania
The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure.
Phase 1 Study Evaluating the Safety and Tolerability of ...
BHV-7000 was safe and well tolerated, without the typical AEs associated with other anti-seizure medications. These findings support the ...
BHV-7000 Open-Label Extension Bipolar Mania Study
The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000 in subjects with bipolar I disorder.
Biohaven Presents New Data with BHV-7000 Once-Daily ...
We are encouraged to see BHV-7000 continue to demonstrate favorable safety and tolerability without dose-limiting toxicities or CNS adverse ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.